Trevena Inc. (TRVN) 6.84 $TRVN Trevena, Inc. Announces

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 11:21 PM

Trevena Inc. (TRVN) 6.84 $TRVN

Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain
BusinessWire - Wed Jun 08, 6:00AM CDT
--- Top-line data for both studies expected in 1Q 2017 -
TRVN: 6.84 (-0.38)

Trevena to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m. EDT in New York.
TRVN: 6.84 (-0.38)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 60.01 (-0.09), TTPH: 3.94 (-0.17), TRVN: 6.84 (-0.38), ADRO: 11.99 (-0.43), ANAC: 99.17 (+0.09)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.01 (-0.09), TRVN: 6.84 (-0.38), TTPH: 3.94 (-0.17), VRTX: 91.49 (-1.00), ADRO: 11.99 (-0.43), AMGN: 154.78 (-2.00), ANAC: 99.17 (+0.09)

Trevena (TRVN) Down on Negative Phase IIb Data on TRV027
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:43AM CDT
Trevena (TRVN) reported disappointing data from a phase IIb study on TRV027, which failed to meet either the primary or secondary endpoints.
TRVN: 6.84 (-0.38), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

Apple, Anacor and Tribune Publishing climb, Trevena skids
AP - Mon May 16, 3:21PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
TRVN: 6.84 (-0.38), TPUB: 13.05 (+0.03), MCK: 185.47 (-1.41), PFE: 35.29 (-0.02), MRD: 15.93 (-1.11), TEX: 21.10 (-0.03), ANAC: 99.17 (+0.09), MRO: 13.42 (-0.84), AAPL: 98.83 (-0.82)

Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
BusinessWire - Mon May 16, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs.
TRVN: 6.84 (-0.38)

Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society
BusinessWire - Wed May 11, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.
TRVN: 6.84 (-0.38)

Trevena reports 1Q loss
Automated Insights - Thu May 05, 6:44AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Thursday reported a loss of $17.8 million in its first quarter.
TRVN: 6.84 (-0.38)

Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 6:00AM CDT
--- Oliceridine pivotal Phase 3 efficacy studies expected to begin this quarter -
TRVN: 6.84 (-0.38)

Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
BusinessWire - Mon May 02, 3:01PM CDT
--- Phase 3 program includes comparisons to both placebo and morphine -
TRVN: 6.84 (-0.38)

Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
BusinessWire - Fri Apr 15, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Heart Failure 2016 includes the 3rd World Congress on Acute Heart Failure, and is taking place in Florence, Italy, May 21-24, 2016.
TRVN: 6.84 (-0.38)

Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York.
TRVN: 6.84 (-0.38)

Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
BusinessWire - Thu Mar 31, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, being held at The Roosevelt Hotel, 123 Baronne Street, New Orleans, LA from Thursday, March 31, 2016 through Saturday, April 2, 2016. The poster presentations highlight data from the oliceridine program, including key data from the Company's Phase 2b trial in acute pain following abdominoplasty.
TRVN: 6.84 (-0.38)

Trevena Reports Full Year 2015 Financial Results
BusinessWire - Wed Mar 09, 6:00AM CST
--- Net loss for the year of $50.5 million, or $1.15 per share -
TRVN: 6.84 (-0.38)

Trevena to Present at Three Upcoming Investor Events in March
BusinessWire - Thu Mar 03, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be presenting at the Cowen 36th Annual Health Care Conference in Boston, the 28th Annual ROTH Conference in Orange County, and the Barclays Global Healthcare Conference in Miami. Details of the conferences are as follows:
TRVN: 6.84 (-0.38)

Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results
BusinessWire - Wed Mar 02, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 9, 2016 at 7:30 a.m. Eastern Time to discuss financial results as of and for the year ended December 31, 2015, as well as 2015 and recent corporate highlights.
TRVN: 6.84 (-0.38)

Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.84 (-0.38), XNCR: 14.48 (-0.18), PDLI: 3.15 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RAI's TrustX Lab Unveils AI Assurance Framework

Pushing the Envelope on AI Control Alright, AI wonks, the Responsible AI Institute just introduced a new sheriff in town. It's called the TrustX Assurance Lab, and it was rolled out during RAISE 2026. We're talking about an independent setup designed to answer whether autonomous AI can stay within its limits. Who's involved? A lot of brainpower from member organizations...

Navigating Car Wreck Chaos for Legal Protection

Clarity Amid Chaos: Handling a Crash in Abilene Let me tell you, if your day starts with a car wreck, every second post-crash counts more than you think. Attorney Chaile Allen out of Abilene's laying down the law on how to protect yourself—because that wreck scene ain't just about bent fenders and bruised egos. It's about getting your ducks in a row for any potential...

Bluerock's Split: What November's Trading Change Means

Bluerock's Strategic Move: Untying the Bundle Ah, Bluerock Acquisition Corp. II has thrown a new bone to the market. Starting November 16, 2026, the firm ain't keeping their Class A ordinary shares and warrants locked in a bundle anymore. This shift comes after they sold 17,250,000 units in their IPO back in September, which also saw underwriters fully clinking their...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

Sound Credit Union, WTA Team Up for Trail Support

Heading Into the Great Outdoors with Every Swipe You ever feel like your money's going nowhere useful? Well, folks in Washington are about to flip the script thanks to Sound Credit Union and the Washington Trails Association (WTA). They've cooked up a slick new money move—a co-branded debit and credit card program—where every swipe backs the state's beloved trails. A...

China-Kenya Trade: Avocado Diplomacy in Action

Avocado: A Trade Symbol with a Pit of Potential Who'd have thought a simple avocado could become such a heavyweight in the international trade arena? But here we are, with Kenyan avocados making a splash on the grand stage at the ninth China International Import Expo in Shanghai. Thanks to zero-tariff treatment, Kenya's prized green exports are rolling into China easier...

Sands China Fosters Cultural Ties with Macau Concert

Macao's Wind Music Legacy Hits a High Note Who would've thought—a gathering of 550 musicians from Macao SAR and France could ignite such a dynamic cross-cultural exchange? Celebrating three decades of musical milestones, the Macau Band Directors Association (MBDA) didn't just throw any old concert but a spectacle that took international collaboration to an upscale...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Fake Profiles Dominate Daters' Trust Issues Today

Trust Erosion in the Digital Dating Arena When it comes to modern dating, we're not talking hearts and flowers anymore; it's more like an elaborate game of detective work. A recent survey from Stud or Dud highlights the harsh reality that blind trust in digital dating profiles is about as outdated as sending a singing telegram. Almost half of the respondents pinned fake...

Angels on Call: Leading Dementia Care Recognition

A Milestone in Dementia Care Excellence Angels on Call Homecare has done what no other U.S. homecare provider seems to have managed—nab recognition from the Alzheimer's Association Curriculum Review while also holding the Purple Flag accreditation. That's a combo meal of accolades in the world of dementia care, and it speaks volumes about their commitment to top-notch...